{"hands_on_practices": [{"introduction": "The Net Monetary Benefit (NMB) framework is a cornerstone of health technology assessment, providing a clear method to evaluate whether a new intervention offers good value for money. This exercise provides fundamental practice in applying the NMB formula to determine a break-even price for a genomic test [@problem_id:4377291]. By integrating health gains ($\\Delta Q$), cost savings, and the payer's willingness-to-pay ($\\lambda$), you will calculate the maximum price at which a test is considered cost-effective, a critical skill for both reimbursement policy and market access strategy.", "problem": "A national payer is evaluating reimbursement for a new comprehensive genomic profiling test used to guide targeted therapy selection in oncology. From the payer perspective over a one-year horizon, the test produces an expected incremental health gain of $\\Delta Q = 0.015$ Quality-Adjusted Life Years (QALYs), where Quality-Adjusted Life Year (QALY) is defined in the conventional health economic sense. The test also produces expected downstream medical cost savings of $\\$1{,}800$ per tested patient due to avoided ineffective therapies and reduced adverse event management. Let the unit test price be $\\$P$, fully reimbursed by the payer. The payer uses a willingness-to-pay threshold of $\\lambda = \\$100{,}000$ per QALY.\n\nUnder the Net Monetary Benefit (NMB) framework, where Net Monetary Benefit (NMB) represents the monetized health gain minus the incremental costs from the payer perspective, assume that all quantities are in expected values, already discounted where appropriate, and that the only incremental costs are the test price and the downstream savings as stated above.\n\nDetermine the break-even unit price $\\$P^{\\ast}$ such that the net monetary benefit equals zero. Express your answer in United States dollars (USD) as an exact value with no rounding.", "solution": "The problem requires the determination of a break-even price for a genomic test based on the Net Monetary Benefit (NMB) framework from a payer's perspective.\n\n### Step 1: Extract Givens\nThe data and definitions provided in the problem statement are:\n- Incremental health gain: $\\Delta Q = 0.015$ Quality-Adjusted Life Years (QALYs).\n- Downstream medical cost savings: $C_{savings} = \\$1,800$.\n- Unit test price: $P$.\n- Payer's willingness-to-pay threshold: $\\lambda = \\$100,000$ per QALY.\n- Framework: Net Monetary Benefit (NMB).\n- Definition of NMB: Monetized health gain minus incremental costs.\n- Condition for break-even price $P^{\\ast}$: $NMB = 0$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is validated against the specified criteria:\n- **Scientifically Grounded**: The problem is based on standard, well-established principles of health economics, specifically cost-effectiveness analysis using the Net Monetary Benefit framework. Key concepts like QALYs, willingness-to-pay thresholds, and payer-perspective economic evaluation are used correctly and are fundamental to the field of health technology assessment. The values provided are realistic for such an evaluation.\n- **Well-Posed**: The problem is clearly defined. It specifies a formula for NMB and asks to solve for a single variable, $P^{\\ast}$, under the condition $NMB=0$. All necessary information is provided to derive a unique solution.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language. It is free of subjective claims.\n- **Completeness and Consistency**: The problem is self-contained. It provides all variables and relationships needed for the calculation ($\\Delta Q$, $\\lambda$, $C_{savings}$) and contains no contradictory information. The assumptions (e.g., expected values, costs considered) are explicitly stated.\n- **Relatedness to Topic**: The problem is directly and correctly situated within the specified topic of *reimbursement policies and economic models for genomic testing* in the field of *precision medicine and genomic diagnostics*.\n\nThe problem is deemed valid as it is a well-posed, scientifically grounded, and objective application of a standard economic model.\n\n### Step 3: Solve the Valid Problem\nThe Net Monetary Benefit (NMB) is an approach to value health outcomes and costs in a common monetary unit. It is defined as the monetized value of the health gain minus the incremental net cost.\n\nThe monetized value of the health gain is the incremental health gain, $\\Delta Q$, multiplied by the societal or payer's willingness-to-pay for that gain, $\\lambda$.\n$$ \\text{Monetized Health Gain} = \\lambda \\times \\Delta Q $$\n\nThe incremental cost from the payer's perspective is the new cost incurred minus any cost savings. The new cost is the price of the test, $P$. The cost savings are given as $C_{savings}$.\n$$ \\text{Incremental Net Cost} = P - C_{savings} $$\n\nTherefore, the NMB equation is:\n$$ NMB = (\\lambda \\times \\Delta Q) - (P - C_{savings}) $$\n\nThe problem asks for the break-even unit price, $P^{\\ast}$, at which the Net Monetary Benefit is zero. We set $NMB = 0$ and solve for $P=P^{\\ast}$.\n$$ 0 = (\\lambda \\times \\Delta Q) - (P^{\\ast} - C_{savings}) $$\n\nRearranging the equation to solve for $P^{\\ast}$:\n$$ P^{\\ast} - C_{savings} = \\lambda \\times \\Delta Q $$\n$$ P^{\\ast} = (\\lambda \\times \\Delta Q) + C_{savings} $$\n\nNow, we substitute the given values into this equation:\n- $\\lambda = 100,000$ (in USD per QALY)\n- $\\Delta Q = 0.015$ (in QALYs)\n- $C_{savings} = 1,800$ (in USD)\n\nFirst, calculate the monetized health gain:\n$$ \\lambda \\times \\Delta Q = 100,000 \\times 0.015 = 1,500 $$\nThis result is in units of USD.\n\nNext, add the cost savings to find the break-even price $P^{\\ast}$:\n$$ P^{\\ast} = 1,500 + 1,800 $$\n$$ P^{\\ast} = 3,300 $$\n\nThus, the break-even unit price for the test, from the payer's perspective, is $\\$3,300$. At this price, the cost of the test is exactly offset by the sum of the monetized health benefits and the downstream cost savings, resulting in a Net Monetary Benefit of zero.", "answer": "$$\n\\boxed{3300}\n$$", "id": "4377291"}, {"introduction": "Reimbursement decisions are almost always made with incomplete evidence, creating uncertainty about a test's true value. This practice moves beyond deterministic calculations to explore decision-making under uncertainty using the concept of the Expected Value of Perfect Information (EVPI) [@problem_id:4377284]. You will learn to quantify the maximum value of resolving all uncertainty before making a coverage decision, providing a rational basis for deciding whether to adopt a technology now or invest in further research.", "problem": "A national payer is evaluating whether to reimburse a comprehensive genomic profiling test for advanced non-small cell lung cancer within a precision oncology program. The payer uses the Net Monetary Benefit (NMB) framework at a fixed willingness-to-pay threshold, where the option implemented under uncertainty is the one that maximizes expected value. The standard of care without the genomic test is the baseline with $NMB$ equal to $0$. Based on current evidence synthesis, the clinical utility of the test is uncertain and takes one of two states: effective or ineffective. If the test is effective, the incremental $NMB$ of adopting the test versus not adopting it is $3{,}000$. If the test is ineffective, the incremental $NMB$ is $-1{,}000$. The payerâ€™s current belief assigns probability $0.6$ to the test being effective and probability $0.4$ to it being ineffective. Under perfect information, the payer can condition the adoption decision on the realized state of clinical utility.\n\nUsing only the definitions of rational choice under uncertainty in cost-effectiveness analysis (maximize expected $NMB$ under current evidence) and the notion that perfect information allows state-contingent choice prior to implementation, determine the Expected Value of Perfect Information (EVPI) for the single decision of whether to reimburse the genomic test. Provide the exact value in United States dollars (USD). Do not round.", "solution": "The problem asks for the determination of the Expected Value of Perfect Information (EVPI) for a decision concerning the reimbursement of a genomic test. The EVPI quantifies the maximum value a decision-maker should be willing to pay for information that would resolve all uncertainty about the states of nature before a decision is made. It is calculated as the difference between the expected value of a decision made with perfect information and the expected value of the optimal decision made under uncertainty.\n\nLet the two states of nature be $S_{\\text{eff}}$, where the test is effective, and $S_{\\text{ineff}}$, where the test is ineffective.\nThe prior probabilities for these states are given as:\n$P(S_{\\text{eff}}) = 0.6$\n$P(S_{\\text{ineff}}) = 0.4$\n\nThe decision-maker has two possible actions: $A_{\\text{adopt}}$, to adopt and reimburse the test, and $A_{\\neg\\text{adopt}}$, to not adopt the test (maintain the standard of care).\n\nThe problem provides the incremental Net Monetary Benefit (NMB) for adopting the test compared to not adopting it for each state of nature. The incremental NMB of not adopting the test is, by definition, $0$. Let $NMB(A, S)$ denote the incremental NMB of action $A$ in state $S$.\n\nThe given payoffs are:\n$NMB(A_{\\text{adopt}}, S_{\\text{eff}}) = 3000$ USD\n$NMB(A_{\\text{adopt}}, S_{\\text{ineff}}) = -1000$ USD\n$NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}}) = 0$ USD\n$NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}}) = 0$ USD\n\nFirst, we determine the optimal decision under current uncertainty. This is the action that maximizes the Expected Net Monetary Benefit (ENMB).\n\nThe ENMB for adopting the test is:\n$$ENMB(A_{\\text{adopt}}) = P(S_{\\text{eff}}) \\times NMB(A_{\\text{adopt}}, S_{\\text{eff}}) + P(S_{\\text{ineff}}) \\times NMB(A_{\\text{adopt}}, S_{\\text{ineff}})$$\n$$ENMB(A_{\\text{adopt}}) = (0.6) \\times (3000) + (0.4) \\times (-1000)$$\n$$ENMB(A_{\\text{adopt}}) = 1800 - 400 = 1400 \\text{ USD}$$\n\nThe ENMB for not adopting the test is:\n$$ENMB(A_{\\neg\\text{adopt}}) = P(S_{\\text{eff}}) \\times NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}}) + P(S_{\\text{ineff}}) \\times NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}})$$\n$$ENMB(A_{\\neg\\text{adopt}}) = (0.6) \\times (0) + (0.4) \\times (0) = 0 \\text{ USD}$$\n\nTo find the optimal decision under uncertainty, we compare the ENMB of the two actions:\n$$ENMB_{\\text{max}} = \\max(ENMB(A_{\\text{adopt}}), ENMB(A_{\\neg\\text{adopt}})) = \\max(1400, 0) = 1400 \\text{ USD}$$\nSince $1400  0$, the optimal decision under uncertainty is to adopt the test ($A_{\\text{adopt}}$). The expected value of this optimal decision is $1400$ USD.\n\nNext, we calculate the Expected Value with Perfect Information (EVwPI). With perfect information, the decision-maker would know the true state of nature before choosing an action. They would choose the action that maximizes the NMB for that specific state.\n\nIf the true state is $S_{\\text{eff}}$, the optimal action is the one that gives the higher NMB:\n$$\\max(NMB(A_{\\text{adopt}}, S_{\\text{eff}}), NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}})) = \\max(3000, 0) = 3000 \\text{ USD}$$\nSo, if the test is known to be effective, the decision-maker would adopt it.\n\nIf the true state is $S_{\\text{ineff}}$, the optimal action is:\n$$\\max(NMB(A_{\\text{adopt}}, S_{\\text{ineff}}), NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}})) = \\max(-1000, 0) = 0 \\text{ USD}$$\nSo, if the test is known to be ineffective, the decision-maker would not adopt it.\n\nThe EVwPI is the expected value of these state-contingent optimal decisions, weighted by the prior probabilities of the states occurring:\n$$EVwPI = P(S_{\\text{eff}}) \\times \\max(3000, 0) + P(S_{\\text{ineff}}) \\times \\max(-1000, 0)$$\n$$EVwPI = (0.6) \\times (3000) + (0.4) \\times (0)$$\n$$EVwPI = 1800 + 0 = 1800 \\text{ USD}$$\n\nFinally, the EVPI is the difference between the Expected Value with Perfect Information and the maximum Expected Net Monetary Benefit under uncertainty:\n$$EVPI = EVwPI - ENMB_{\\text{max}}$$\n$$EVPI = 1800 - 1400 = 400 \\text{ USD}$$\n\nThe EVPI represents the expected gain from avoiding the consequences of making a suboptimal choice. The suboptimal choice occurs when adopting the test ($A_{\\text{adopt}}$) if the state is actually $S_{\\text{ineff}}$. The loss from this error, or \"opportunity loss,\" is the value of the best action in that state minus the value of the chosen action: $0 - (-1000) = 1000$. This error occurs with probability $P(S_{\\text{ineff}}) = 0.4$. The expected opportunity loss is thus $0.4 \\times 1000 = 400$, which is the EVPI.", "answer": "$$\\boxed{400}$$", "id": "4377284"}, {"introduction": "To create robust economic models, we must account for the fact that multiple inputs, like costs and health effects, are uncertain simultaneously. This advanced, hands-on exercise introduces Probabilistic Sensitivity Analysis (PSA), a powerful computational technique used to propagate input uncertainty through a model to understand the resulting uncertainty in the decision outcome [@problem_id:4377329]. By modeling incremental costs ($\\Delta C$) and QALYs ($\\Delta Q$) as random variables, you will calculate the overall probability that a genomic test is cost-effective, reflecting the sophisticated analyses that underpin modern reimbursement submissions.", "problem": "A health system is evaluating whether to reimburse a new genomic testing strategy in oncology within the framework of cost-effectiveness analysis. Let Net Monetary Benefit (NMB) be defined as $NMB=\\lambda\\,\\Delta Q-\\Delta C$, where $\\lambda$ is the willingness-to-pay threshold in dollars per Quality-Adjusted Life Year (QALY), $\\Delta Q$ is the incremental QALYs gained by adopting the genomic test relative to usual care, and $\\Delta C$ is the incremental cost in dollars. Quality-Adjusted Life Year (QALY) is a health outcome measure, and Net Monetary Benefit (NMB) is a monetary transformation that facilitates decision rules in reimbursement. Assume $(\\Delta C, \\Delta Q)$ follows a joint normal distribution with specified means, standard deviations, and correlation, and decision-making is based on the probability that $NMB0$. You must start from the definitions of $NMB$, properties of linear transformations of jointly normal random variables, and the cumulative distribution function of the standard normal distribution. Do not use any pre-derived shortcut formulas directly stated in the problem; derive the necessary relationships from these fundamental bases.\n\nYour task is to write a program that, for each test case below, computes the probability $\\mathbb{P}(NMB0)$ under the joint normal assumptions. If a test case produces a degenerate distribution where the variance of $NMB$ equals $0$, define $\\mathbb{P}(NMB0)$ to be $1$ when $NMB$ is strictly positive with probability $1$, and $0$ otherwise. All probabilities must be expressed as decimals. No Monte Carlo simulation is permitted; compute the exact probability implied by the joint normal model.\n\nUse the following test suite, where each case is specified by $(\\mu_C, \\sigma_C, \\mu_Q, \\sigma_Q, \\lambda, \\rho)$ with $\\mu_C$ in dollars, $\\sigma_C$ in dollars, $\\mu_Q$ in QALYs, $\\sigma_Q$ in QALYs, $\\lambda$ in dollars per QALY, and $\\rho$ the Pearson correlation between $\\Delta C$ and $\\Delta Q$:\n\n- Case $1$: $(\\$1{,}000,\\$300,0.02,0.005,\\$150{,}000,0)$\n- Case $2$: $(\\$1{,}000,\\$300,0.02,0.005,\\$50{,}000,0)$\n- Case $3$: $(\\$1{,}000,\\$300,0.02,0.005,\\$10{,}000,0)$\n- Case $4$: $(\\$1{,}000,\\$300,0.02,0.005,\\$150{,}000,0.5)$\n- Case $5$: $(\\$1{,}000,\\$0,0.02,0,\\$50{,}000,0)$\n\nRequirements:\n- For each case, compute $\\mathbb{P}(NMB0)$ as a float rounded to six decimal places.\n- The final program output must be a single line containing a comma-separated list of the five rounded probabilities enclosed in square brackets, for example, $[x_1,x_2,x_3,x_4,x_5]$.", "solution": "The problem requires the computation of the probability that the Net Monetary Benefit ($NMB$) is greater than zero, i.e., $\\mathbb{P}(NMB  0)$, under a joint normal model for incremental costs and effects. The solution must be derived from fundamental principles.\n\nThe Net Monetary Benefit is defined as a linear transformation of the incremental QALYs, $\\Delta Q$, and the incremental cost, $\\Delta C$:\n$$NMB = \\lambda \\Delta Q - \\Delta C$$\nwhere $\\lambda$ is the willingness-to-pay threshold.\n\nWe are given that the pair of random variables $(\\Delta C, \\Delta Q)$ follows a joint normal distribution. Let the parameters of this distribution be:\n- Mean of $\\Delta C$: $\\mathbb{E}[\\Delta C] = \\mu_C$\n- Standard deviation of $\\Delta C$: $\\sqrt{\\text{Var}(\\Delta C)} = \\sigma_C$\n- Mean of $\\Delta Q$: $\\mathbb{E}[\\Delta Q] = \\mu_Q$\n- Standard deviation of $\\Delta Q$: $\\sqrt{\\text{Var}(\\Delta Q)} = \\sigma_Q$\n- Correlation between $\\Delta C$ and $\\Delta Q$: $\\rho = \\frac{\\text{Cov}(\\Delta C, \\Delta Q)}{\\sigma_C \\sigma_Q}$\n\nA fundamental property of multivariate normal distributions is that any linear combination of the components is also normally distributed. The $NMB$ is a linear combination of $\\Delta Q$ and $\\Delta C$ with coefficients $\\lambda$ and $-1$, respectively. Therefore, $NMB$ itself follows a normal distribution, which can be denoted as $NMB \\sim \\mathcal{N}(\\mu_{NMB}, \\sigma^2_{NMB})$. To find $\\mathbb{P}(NMB  0)$, we must first determine the parameters of this distribution, its mean $\\mu_{NMB}$ and variance $\\sigma^2_{NMB}$.\n\n**1. Derivation of the Mean of NMB ($\\mu_{NMB}$)**\n\nThe expectation operator is linear. Applying this property to the definition of $NMB$:\n$$ \\mu_{NMB} = \\mathbb{E}[NMB] = \\mathbb{E}[\\lambda \\Delta Q - \\Delta C] $$\n$$ \\mu_{NMB} = \\lambda \\mathbb{E}[\\Delta Q] - \\mathbb{E}[\\Delta C] $$\nSubstituting the given means:\n$$ \\mu_{NMB} = \\lambda \\mu_Q - \\mu_C $$\n\n**2. Derivation of the Variance of NMB ($\\sigma^2_{NMB}$)**\n\nThe variance of a linear combination of two random variables $X$ and $Y$, in the form $aX + bY$, is given by $\\text{Var}(aX + bY) = a^2 \\text{Var}(X) + b^2 \\text{Var}(Y) + 2ab \\text{Cov}(X, Y)$.\nApplying this to $NMB = \\lambda \\Delta Q + (-1) \\Delta C$, we have $a = \\lambda$, $b = -1$, $X = \\Delta Q$, and $Y = \\Delta C$.\n$$ \\sigma^2_{NMB} = \\text{Var}(NMB) = \\text{Var}(\\lambda \\Delta Q - \\Delta C) $$\n$$ \\sigma^2_{NMB} = \\lambda^2 \\text{Var}(\\Delta Q) + (-1)^2 \\text{Var}(\\Delta C) + 2(\\lambda)(-1) \\text{Cov}(\\Delta Q, \\Delta C) $$\nWe are given the standard deviations $\\sigma_Q$ and $\\sigma_C$, so $\\text{Var}(\\Delta Q) = \\sigma_Q^2$ and $\\text{Var}(\\Delta C) = \\sigma_C^2$. The covariance can be expressed in terms of the correlation coefficient $\\rho$: $\\text{Cov}(\\Delta Q, \\Delta C) = \\rho \\sigma_Q \\sigma_C$. Substituting these into the variance equation:\n$$ \\sigma^2_{NMB} = \\lambda^2 \\sigma_Q^2 + \\sigma_C^2 - 2 \\lambda \\rho \\sigma_Q \\sigma_C $$\nThe standard deviation of $NMB$ is $\\sigma_{NMB} = \\sqrt{\\sigma^2_{NMB}}$.\n\n**3. Calculation of the Probability $\\mathbb{P}(NMB  0)$**\n\nGiven that $NMB \\sim \\mathcal{N}(\\mu_{NMB}, \\sigma^2_{NMB})$, we can standardize this variable to a standard normal variable $Z \\sim \\mathcal{N}(0, 1)$, which is defined as:\n$$ Z = \\frac{NMB - \\mu_{NMB}}{\\sigma_{NMB}} $$\nWe want to find the probability $\\mathbb{P}(NMB  0)$. We can express this inequality in terms of the standardized variable $Z$. Assuming $\\sigma_{NMB}  0$:\n$$ NMB  0 \\implies NMB - \\mu_{NMB}  - \\mu_{NMB} \\implies \\frac{NMB - \\mu_{NMB}}{\\sigma_{NMB}}  - \\frac{\\mu_{NMB}}{\\sigma_{NMB}} $$\n$$ \\mathbb{P}(NMB  0) = \\mathbb{P}\\left(Z  - \\frac{\\mu_{NMB}}{\\sigma_{NMB}}\\right) $$\nLet $\\Phi(\\cdot)$ be the cumulative distribution function (CDF) of the standard normal distribution. By the symmetry of the normal distribution, $\\mathbb{P}(Z  -z) = \\mathbb{P}(Z  z)$. Therefore:\n$$ \\mathbb{P}(NMB  0) = \\mathbb{P}\\left(Z  \\frac{\\mu_{NMB}}{\\sigma_{NMB}}\\right) = \\Phi\\left(\\frac{\\mu_{NMB}}{\\sigma_{NMB}}\\right) $$\nThis expression provides the exact probability assuming a non-degenerate distribution for $NMB$.\n\n**4. Handling the Degenerate Case ($\\sigma^2_{NMB} = 0$)**\n\nA degenerate case occurs if $\\sigma^2_{NMB} = 0$. This happens if and only if both $\\sigma_C$ and $\\sigma_Q$ are zero (since $\\lambda  0$). In this situation, $\\Delta C$ and $\\Delta Q$ are constants equal to their means, $\\mu_C$ and $\\mu_Q$. Consequently, $NMB$ is also a constant, equal to its mean:\n$$ NMB = \\mu_{NMB} = \\lambda \\mu_Q - \\mu_C $$\nThe probability $\\mathbb{P}(NMB  0)$ is determined deterministically. Following the problem statement:\n- If $\\mu_{NMB}  0$, then $NMB$ is always positive, so $\\mathbb{P}(NMB  0) = 1$.\n- If $\\mu_{NMB} \\leq 0$, then $NMB$ is never strictly positive, so $\\mathbb{P}(NMB  0) = 0$.\n\nThe following program implements these derived formulas to compute the probability for each test case.", "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\nfrom scipy.stats import norm\n\ndef solve():\n    \"\"\"\n    Computes the probability that the Net Monetary Benefit (NMB) is positive\n    for a series of cost-effectiveness analysis scenarios.\n    \"\"\"\n    \n    # Define the test cases from the problem statement.\n    # Each case is a tuple: (mu_C, sigma_C, mu_Q, sigma_Q, lambda, rho)\n    test_cases = [\n        (1000, 300, 0.02, 0.005, 150000, 0),\n        (1000, 300, 0.02, 0.005, 50000, 0),\n        (1000, 300, 0.02, 0.005, 10000, 0),\n        (1000, 300, 0.02, 0.005, 150000, 0.5),\n        (1000, 0, 0.02, 0, 50000, 0),\n    ]\n\n    results = []\n    for case in test_cases:\n        mu_C, sigma_C, mu_Q, sigma_Q, lam, rho = case\n\n        # Calculate the mean of the Net Monetary Benefit (NMB)\n        # E[NMB] = E[lambda * dQ - dC] = lambda * E[dQ] - E[dC]\n        mu_nmb = lam * mu_Q - mu_C\n\n        # Calculate the variance of the Net Monetary Benefit (NMB)\n        # Var(NMB) = Var(lambda * dQ - dC)\n        # = lambda^2*Var(dQ) + Var(dC) - 2*lambda*Cov(dQ, dC)\n        # = lambda^2*sigma_Q^2 + sigma_C^2 - 2*lambda*rho*sigma_Q*sigma_C\n        var_nmb = (lam**2 * sigma_Q**2) + (sigma_C**2) - (2 * lam * rho * sigma_Q * sigma_C)\n\n        if var_nmb == 0:\n            # Handle the degenerate case where NMB is a constant\n            # The probability is 1 if the constant NMB  0, and 0 otherwise.\n            prob = 1.0 if mu_nmb  0 else 0.0\n        else:\n            # Handle the non-degenerate case\n            # NMB is normally distributed. Standardize it to find P(NMB  0).\n            # P(NMB  0) = P((NMB - mu)/sigma  -mu/sigma) = P(Z  mu/sigma)\n            sigma_nmb = np.sqrt(var_nmb)\n            z_score = mu_nmb / sigma_nmb\n            prob = norm.cdf(z_score)\n\n        # Format the result to six decimal places and append to the list\n        results.append(f\"{prob:.6f}\")\n\n    # Final print statement in the exact required format.\n    print(f\"[{','.join(results)}]\")\n\nsolve()\n```", "id": "4377329"}]}